JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients (Q46113435)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2009

Language	Label	Description	Also known as
English	JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients	scientific article published in February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

0 references

Nicola Polverelli

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

object named as

Lucia Catani

4

0 references

Francesca Palandri

object named as

Francesca Palandri

1

0 references

Giovanni Martinelli

7

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Michele Baccarani

8

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Emanuela Ottaviani

2

object named as

Emanuela Ottaviani

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Mauro Fiacchini

6

object named as

Mauro Fiacchini

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

3

object named as

Federica Salmi

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

author name string

Nicola Vianelli

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

language of work or name

0 references

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

50

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

247-253

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

Essential thrombocythaemia: challenges and evidence-based management

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

A long-term retrospective study of young women with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Identifiers

10.1080/10428190802688152

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46113435&oldid=2093251234"